CTLA4 and neoplasm: These results suggest that the novel mAb directly affects the CTLA-4 function on tumor cells by inhibiting the downstream survival pathways, such as that of PI3K, and by inducing apoptosis by downregulating Akt, thus acting as an agonistic antibody on tumor cells.